Chen ZX, Li J, Liu WB, Zhang SR, Sun H. Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer. World J Clin Cases 2022; 10(5): 1498-1507 [PMID: 35211587 DOI: 10.12998/wjcc.v10.i5.1498]
Corresponding Author of This Article
Hao Sun, MM, Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Sha pingba District, Chongqing 400030, China. sunhao68@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 16, 2022; 10(5): 1498-1507 Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1498
Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer
Zhi-Xiong Chen, Jin Li, Wen-Bin Liu, Shou-Ru Zhang, Hao Sun
Zhi-Xiong Chen, Hao Sun, Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, Chongqing 400030, China
Jin Li, Department of Ultrasound, The Fifth People's Hospital of Chongqing, Chongqing 400062, China
Wen-Bin Liu, Department of Hepatobiliary and Pancreatic Oncology, Chongqing University Cancer Hospital, Chongqing 400030, China
Shou-Ru Zhang, Department of Teaching and Research Section, Chongqing University Cancer Hospital, Chongqing 400030, China
Author contributions: Sun H and Chen ZX concepted and designed; Chen ZX and Li J; Chen ZX, Liu WB, and Zhang SR analysed the data and interpretation; all authors wrote the manuscript and approval of the final manuscript.
Institutional review board statement: All procedures performed in studies that involved human participants were in accordance with the ethical standards of the institutional and/or national research committee, and the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The present study was approved by the Ethics Committee of CUCH.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated and analyzed in the present study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao Sun, MM, Department of Gastrointestinal Cancer Center, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Sha pingba District, Chongqing 400030, China. sunhao68@sina.com
Received: September 18, 2021 Peer-review started: September 18, 2021 First decision: October 27, 2021 Revised: November 19, 2021 Accepted: January 11, 2022 Article in press: January 11, 2022 Published online: February 16, 2022 Processing time: 145 Days and 23.2 Hours
ARTICLE HIGHLIGHTS
Research background
Elderly patients with peritoneal metastatic gastric cancer (PGC) have poor tolerance to intensive treatment, such as cytoreductive surgery plus hyperthermic perfusion chemotherapy (HIPEC). To date, no guidelines or consensus has standardized the HIPEC composition. However, elemene, a Chinese herbal extract with anti-cancer activity and low toxicity, turns out to be a promising ingredient for HIPEC.
Research motivation
The study aims to determine whether implementing elemene in lobaplatin-based HIPEC benefits elderly PGC patients during chemotherapy.
Research objectives
The study aims to explore the clinical effectiveness and potential side effects of elemene-containing lobaplatin-based HIPEC in elderly PGC patients.
Research methods
The included patients were assigned into two groups: patients who received elemene-containing lobaplatin-based HIPEC plus oxaliplatin and capecitabine (CapeOx) treatment (group M) and patients who received elemene-free lobaplatin-based HIPEC plus CapeOx treatment (group L). The incidence of complications such as myelosuppression, immune function (CD4/CD8 ratio), average length of hospital stay, and prognosis were compared between these two groups.
Research results
There was no significant difference in the incidence of complications and overall survival between the two groups during hospitalization. In addition, supplementing elemene in HIPEC lessened the myelosuppression (P = 0.027) and shortened the length of hospital stay (P = 0.045) of elderly PGC patients.
Research conclusions
The administration of elemene led to the amelioration of myelosuppression in elderly PGC patients.
Research perspectives
The present study sheds light on the implemention of an elemene-containing HIPEC therapeutic strategy for elderly patients with PGC.
